Using cyclosporin A (CsA) to inhibit P-glycoprotein (P-gp) funcoxidative phosphorylation, such as cyanide and azide, thereby tion we showed previously that there was a discordance depleting cellular ATP and inhibiting all energy-dependent between the ability of acute myeloid leukemic (AML) blast cells processes. This strategy was used originally to demonstrate the to accumulate daunorubicin and P-gp antigen expression (Xie ATP dependence of P-gp, 7 and more recently has been shown et al, Leukemia 1995; 9: 1882-1887). This discordance suggests to inhibit drug efflux via MRP. 8, 9 We now report that it also that a CsA-sensitive drug efflux mechanism distinct from P-gp is expressed in many clinical samples. In the present study appears to show the presence of high levels of non-P-gp The following human cell lines were used to study energy- AML lines OCI/AML 1-5, established in this Institute. In
U1 (bladder), MCF7 (breast), SKOV3 (ovary), and HCT8 (colon). Parental HeLaS3 cervical carcinoma cells, and the multidrug resistance-associated protein (MRP) expressing vari-

Introduction
ant HeLaJ2, 4 were kindly supplied by Dr Raymond Baker, Roswell Park Cancer Institute, Buffalo, NY, USA. With the P-glycoprotein is a member of a large class of membrane exception of the CCRF-CEM VLB 0.1 and 1.0 cells, none of transporters coded for by the ATP-binding cassette (ABC) gene these lines showed increased expression of P-glycoprotein as superfamily. 1, 2 The physiological function of most of these assessed using Western blotting with monoclonal antibody ABC transporter gene products is unknown, but an additional C219, 10 or surface immunolabelling with the MRK-16 antimember, multidrug resistance associated protein (MRP), has body.
11
recently been shown to produce resistance to a range of natural products such as anthracyclines and vinca alkaloids by an active transport mechanism similar to that of P-gp. 3, 4 Although
Clinical samples expression of MRP has been observed in leukemic blasts its clinical significance is still unknown. 5 When we compared Peripheral blood samples containing at least 50% leukemic the amount of P-gp antigen expressed on the cell membrane blasts were obtained from 49 patients with acute myeloid leuto the modulating effects of the P-gp inhibitor cyclosporin A kemia, either at initial presentation (27 patients) or with recur-(CsA) on daunorubicin accumulation, we found little correrent disease following prior chemotherapy (22 patients) . lation between the two assays in a series of AML patients. 6 Induction chemotherapy consisted of a standard protocol of Compared to the results obtained with P-gp expressing cell high dose cytosine arabinoside and daunorubicin. Blasts were lines, the AML samples showed generally greater transport separated by density gradient centrifugation, washed, counted function in relation to Pgp antigen expression. This suggests and resuspended in PBS at 1 × 10 6 /ml. that the modulating effect of CsA on daunorubucin accumulation, commonly regarded as a P-gp functional assay, can detect drug efflux mechanisms that are antigenically distinct Flow cytometric measurement of P-gp from classical Pg-p. Because CsA might be a poor inhibitor of some of these putative non-P-gp transporters, the functional Cell surface expression of Pgp was detected using the MRKassay was modified by replacing CsA with agents that inhibit 16 antibody (gift of Dr T Tsuruo, University of Tokyo), which recognizes an external epitope of the human MDR-1 gene product. 11 Because epitope masking can impair labelling of incubated for 30 min with a 1:10 dilution of goat gammaactin cDNA, the original probe was removed by boiling the blots in 0.5% SDS for 5 min. Expression of MRP in human globulin on ice, to block non-specific binding sites. They were then incubated with 20 g/ml MRK-16 antibody for a further cell lines was measured using Northern blotting. Results were compared to the level of ␤ actin expression, and for compari-30 min on ice. An MRK-16 dilution curve using CCRF-CEM VLB 0.1 cells showed that this was a saturating concentration son between the cell lines they were normalized with the ratio MRP:␤ action for HeLaS3 cells set as 1. of antibody. After washing twice with cold PBS, the cells were incubated with a 1:25 dilution of phycoerythrin (PE)-conjugated F(ab′) 2 goat anti-mouse immunoglobulin (Dakopatts, Denmark) on ice for 30 min, and washed twice. 6 
Results
Fluorescence calibration beads were used to obtain an estimate of the number of antigenic sites per cell. These caliMeasurement of P-gp function and antigen expression in acute leukemia samples bration beads (SpheroTech, Libertyville, IL, USA), consist of a mixture of particles at six different fluorescent intensities, calibrated to give the mean equivalent soluble fluorochrome Using the methods described above, we have previously found that in the blast cells of the majority of AML patients, (MESF). Thus the mean number of phycoerythrin molecules bound to the cell surface can be estimated.
P-gp antigen expression is detectable, and daunorubicin accumulation is increased in the presence of CsA, an inhibitor of P-gp function. Unexpectedly, there appeared to be little correlation between the amount of P-gp detected and the Flow cytometric measurement of daunorubicin accumulation functional assay. 6 In the present study we used fluorescent calibration beads to quantitate the number of phycoerythrin molecules bound per cell, thereby obtaining an estimate to Cells were incubated in 3 g/ml daunorubicin, which is naturally fluorescent, at a concentration of 1 × 10 6 cells/ml, ±3 the actual number of P-gp antigenic sites. Although the stoichiometry of the immunolabelling technique is unlikely to be g/ml CsA at 37°C for 30 min. Increased efflux of daunorubicin by Pgp causes a decrease in daunorubicin accumulation strictly 1:1, the error introduced is small in relation to the range of values seen between individual samples, and the use that can be reversed by the addition of CsA. The mean fluorescence from each daunorubucin and daunorubucin + CsA of standardized measurement units facilitates comparison between the levels of P-gp found in different cell populations. sample was recorded, and the Pgp functional activity expressed as the percentage increase in daunorubicin fluorAs seen in Figure 1 , there is a clear correlation between transport function and antigen expression in a series of CCRF-CEM escence after CsA treatment, ie: human T lymphoblast lines, which are well characterized with
regard to their P-gp expression. When the data for the cell lines and AML samples from patients were plotted using the same axis scales, it was observed that compared to the cell In addition to CsA, which is a classical P-gp inhibitor, cellular lines, the clinical samples showed relatively low levels of ATP was depleted by the addition of 2 mm KCN, 2 mm NaN 3 , or 1 mm dinitrophenol, in order to inhibit all energy-dependent drug transport mechanisms. Thus a % functional activity (KCN etc) was calculated similar to the % functional activity (CsA).
Flow cytometry was done using an Epics Elite cell sorter (Coulter Electronics, Hialeah, FL, USA) equipped with an aircooled argon laser emitting at 488 nm and operating at 15 mW. Forward and side scatter signals were collected using linear amplification to define the blast population, from which the fluorescence data were taken. Phycoerythrin fluorescence was measured with a 575 nm bandpass filter using logarithmic amplification, and daunorubicin fluorescence with the same filter using linear amplification. A minimum of 20 000 events were collected for each sample.
Measurement of Pgp and MRP mRNA
Cells grown at exponential stage were harvested and subjected to total RNA isolation using the guanidinium isothiocyanate method according to Chomczynski and Sacchi.
13 Total RNA 15 g was then size fractionated on a denaturing formaldehyde agarose (1%) gel, transferred to Hybond N Membrane (Amersham, Arlington Heights, IL, USA), and probed with a ( c.p.m./g, random priming method.) For reprobing with ␤-MRK-16 labelling but some of the samples showed disproportionately high increases in daunorubicin accumulation with CsA, relative to the number of P-gp antigenic sites per cell ( Figure 1 ). This suggests that in a significant proportion of AML patients, CsA-inhibitable daunorubicin efflux can occur by mechanisms that are antigenically distinct from P-gp. It is now established that energy-dependent efflux of daunorubicin can result from overexpression of MRP, another member of the ABC family of membrane transporters. 8, 14 Furthermore, MRP expression has recently been reported in some AML patients. 5, 15 MRP is less sensitive than P-gp to CsA inhibition. 8 We were therefore interested in determining if the concentration of CsA used in our experiments would be effective against an MRP-mediated reduction in daunorubicin accumulation. We used the well-characterized HeLaJ2 cell line containing an amplified MRP gene 4 to investigate this question. We observed no measurable increase in daunorubicin accumulation when these cells were treated with 3 g/ml CsA (data not shown). Therefore, the CsA-stimulated accumulation of daunorubicin observed in the AML samples is not likely due to expression of MRP.
Effects of metabolic inhibitors on the accumulation of daunorubicin by cell lines
In addition to agents such as CsA or verapamil, that probably act by competitive inhibition of substrate binding sites, drug efflux via P-gp can be reversed using ATP-depleting agents dependent processes influencing daunorubicin accumulation. In other words, substitution of ATP-depleting agents for CsA in the daunorubicin accumulation assay will give a sumescence values were similar to those of controls that were preloaded with daunorubicin in the absence of KCN. This revermation of all energy-dependent drug transport processes, regardless of whether these are sensitive to classical P-gp sal effect of glucose is consistent with our hypothesis that KCN treatment inhibits an ATP-dependent daunorubicin efflux inhibitors such as CsA or verapamil.
Initially, the five human AML cell lines OCI/AML 1-5 were mechanism. In addition to active extrusion via P-gp, cellular accumuinvestigated, since these have been extensively characterized in our Institution, and express very low levels of P-gp. This lation of weak bases such as daunorubicin may be influenced by the pH gradient across the surface membrane. 16, 17 A relawas confirmed in the present series of experiments by demonstrating a lack of MRK-16 staining and low levels of CsAtive reduction in intracellular pH may cause decreased drug accumulation, because the equilibrium is shifted to the prodependent increases in daunorubicin accumulation in all five lines. Cells were treated with 2 mm KCN, 2 mm sodium azide, tonated form which diffuses much more slowly through lipid bilayers. To test the possibility that KCN was causing or 1 mm dinitrophenol (DNP) in glucose-free medium, in an assay that was otherwise identical to the P-gp functional assay increased daunorubicin accumulation by producing cellular acidosis, thereby altering drug partitioning across the surface described above. Similar results were obtained for all five AML lines, with a mean increase in daunorubicin accumumembrane, cells were loaded with the pH-sensitive dye SNARF-1, and relative intracellular pH values measured using lation of 122% ± 25 s.d. using KCN, compared to 6% ± 4 s.d. when CsA was used as the modulating agent. Similar results a standard ratio metric flow cytometry assay. 18 Within the sensitivity of the assay (approximately 0.2 pH units) there was were obtained for all three metabolic inhibitors, and for this reason most subsequent experiments were done using 2 mm no detectable change in intracellular pH during the 30 min exposure to KCN, suggesting that acidification of cytoplasm is KCN only.
In order to establish that the increases in daunorubicin unlikely to account for the increased daunorubicin uptake. accumulation seen with KCN treatment were due to the inhibition of an ATP-dependent efflux mechanism, 5 mm glucose was added at the end of the 30 min incubation period. The KCN-sensitive daunorubicin accumulation and MRP expression in P-gp-negative human cell lines cells were maintained in daunorubicin ± KCN throughout the experiment. In the presence of continued exposure to KCN, glucose allows ATP generation to take place by glycolysis. 7 The increased daunorubicin accumulation seen in the OCI/AML cell lines following KCN treatment suggests that As shown in Figure 2 , addition of glucose to cells pre-loaded with daunorubicin in the presence of KCN resulted in the energy-dependent mechanisms other than classical P-gp are expressed in these cells, and inhibit drug uptake. To date the rapid loss of drug, so that by 20 min daunorubicin fluor-only other ABC transporter known to be expressed in human were comparable to those seen with CsA, suggesting that Pgp overexpression or some other non-P-gp but CsA-sensitive cells and capable of transporting daunorubicin is MRP. We therefore compared the expression of MRP to the effect of mechanism was a major determinant of the reduced daunorubicin uptake. In others, the increase was much greater with KCN on daunorubicin accumulation. In addition to the OCI/AML lines, we examined parental CCRF-CEM T lympho-KCN suggesting the presence of both CsA-responsive and nonresponsive energy-dependent daunorubicin transport mechblasts, and a series of human carcinoma lines including parental HeLa cells and the MRP overexpressing line HeLaJ2.
anisms (Figure 4) . These results are summarized in Figure 5 .
In the majority of cases, accumulation of daunorubicin was None of these cell lines overexpresses P-gp. Expression of MRP was determined by comparing levels of mRNA for MRP increased in the presence of 2 mm KCN. The magnitude of this effect varied widely between patients, ranging from no to those for ␤ actin, using Northern blotting, these results then being normalized to MRP expression by parental HeLaS3 significant effect to Ͼ200% increases in daunorubicin accumulation. The trend was for larger increases in drug cells, which was set an an arbitrary value of 1. As shown in Figure 3 , there was a wide range of values between the 12 uptake with KCN treatment in patients with recurrent disease following previous chemotherapy using daunorubicin-concell lines. As expected, the highest level of MRP expression was found in HeLaJ2 cells, but significant levels were also taining regimens compared to patients at initial diagnosis (mean increase 123% ± 51 s.d., compared to 95% ± 57 s.d.; seen in the OCI/AML lines AML1 and AML4, and in the HCT8 colon cancer line. In all cases, daunorubicin uptake was P Ͼ 0.05 using Student's t-test). increased by co-incubation with 2 mm KCN, but there was no correlation with the level of MRP expression. The results for the OCI/AML lines were particularly striking. As illustrated in Discussion Figure 3 , despite expressing very low levels of MRP mRNA, the lines AML2, AML3 and AML5 showed similar increases in
Using neuraminidase pretreatment and a sensitive immunofluorescence technique, P-gp could be detected in almost all daunorubicin uptake with KCN treatment to those seen in the MRP expressing lines AML1 and AML4.
cases of AML. However, the levels of expression were 30-100 times lower than those seen in P-gp overexpressing CCRF-CEM cell lines. Considerable interpatient heterogeneity was seen in the levels of both P-gp antigen expression, and in
Comparative effects of CsA and KCN on daunorubicin uptake by AML blasts cyclosporin-inhibitable daunorubicin efflux. Although the latter is widely taken to be a measure of P-gp functional activity, there was no significant correlation with P-gp antigen A comparison was made between the effects of CsA and KCN on daunorubicin accumulation by leukemic blasts obtained expression by AML leukemic blasts. 6 This finding is consistent with some other recent reports for AML, 19, 20 and in contrast from patients. In some clinical samples the effects of KCN to chronic lymphocytic leukemia, where the daunorubicin accumulation assay has been shown to correlate closely with the levels of P-gp antigen and mRNA expression.
12,21
Replotting the AML patient results on the same axis scale as that for the P-gp expressing cell lines shows that in many cases the patient samples have much higher activity in the functional assay than would be predicted from the amount of P-gp antigen on the cell surface ( Figure 1 ). One explanation of this finding might be overexpression of MRP, the only other ABC transporter that is known to be expressed in AML and to be capable of effluxing daunorubicin. However, CsA is a poor inhibitor of MRP. Using a concentration of 3 m CsA we found no significant increases in uptake of daunorubicin by the MRP amplified line HeLaJ2, or the leukemic lines OCI/AML1 and 4, both of which showed considerable MRP
Figure 3
Correlation between the MRP mRNA level and percentage increase in daunorubicin accumulation after KCN treatment in a Figure 4 Overlay histograms showing uptake of daunorubicin by leukemic blasts from an AML patient, comparing the effects of CsA series of low P-gp expressing human leukemic and epithelial tumor cell lines.
and KCN to control values.
Figure 5
Comparison between the modulating effects of CsA and KCN on daunorubicin accumulation by AML blasts obtained from: (a) patients at initial diagnosis, and (b) patients with recurrent disease following previous chemotherapy.
expression by Northern blotting. A more likely explanation is be ABC transporters, or other mechanisms. If this interpretation is correct, then some AML patient samples show daunothat a novel CsA-sensitive mechanism is reducing daunorubicin accumulation in many AML samples. rubicin efflux rates that are similar to those seen in CCRF-CEM VLB 1.0 cells expressing Ͼ100 000 P-gp antigenic sites per A large number of ABC transporters have now been identified in human cells on the basis of sequence homologies in cell (see Figure 1) . We do not believe that the energy-dependent drug transport phenomena observed in the leukemia the highly conserved ATP binding region. 1 The function of most of these is unknown. Because of the possibility that an patients can be explained simply on the basis of variable expression of P-gp and MRP, since large increases were seen additional ABC transporter might be active in some AML samples, the functional assay was modified using ATP-depletin daunorubicin accumulation following KCN treatment were also seen in AML lines that express very low levels of P-gp ing agents in order to inhibit all energy-dependent processes. This strategy was originally used to demonstrate the ATP and MRP. More likely, this study suggests the presence of a novel mechanism(s) in some patient blast cells. dependence of P-gp, 7 and has recently been shown to inhibit MRP. 8, 22 It is likely to provide a broader spectrum of activity Identification of new drug resistance mechanisms usually involves the use of cell lines selected by in vitro drug than agents such as CsA that inhibit substrate binding sites.
Generalized ATP depletion resulted in large increases in exposure. Stepwise increases in drug concentrations over time can result in very high levels of resistance to agents such as daunorubicin accumulation by a wide range of human cell lines, including some that express little or no P-gp or MRP.
anthracyclines or vinca alkaloids, frequently associated with increased P-gp or MRP expression. However, drug selection Addition of glucose, which allows ATP generation by glycolysis, reversed this effect. Alterations in intracellular pH have is clearly not essential for this since elevated P-gp or MRP levels are also seen in some untreated cancer patients, possbeen shown to affect cellular accumulation and subcellular distribution of weakly basic drugs such as daunorubicin. 16 ibly because the cancer is derived from a normal tissue that naturally expresses the resistance mechanism, or as a genetic However, no significant changes in intracellular pH were detected during 30 min exposure to 2 mm KCN. The most alteration occurring as part of the neoplatic process. It is now recognized that the ABC transporter family is extremely likely explanation for these findings is that ATP depletion inhibits an energy-dependent process that reduces daunorubdiverse in nature, 1 and that several members are capable of conferring drug resistance in a wide range of species. The icin accumulation.
Comparison of the modulating effects of CsA and KCN in human genome may contain many ABC transporters which have not yet been identified and it would not therefore be the AML samples shows considerable interpatient heterogeneity ( Figure 5 ). In some cases neither agent increased drug surprising if some of these as yet uncharacterized ABC transporters were constitutively expressed in AML blasts, and capaccumulation, indicating that no energy-dependent processes were active. In others the effects of CsA and KCN were able of transporting daunorubicin. The constitutive expression of high levels of non-P-gp drug roughly comparable, suggesting the expression of P-gp or a closely related transporter. In striking contrast, however, some transporters might be one explanation for the comparatively weak association between increased P-gp expression and patient samples showed very little modulation of daunorubicin uptake by CsA, but large increases with KCN. We propose treatment outcome in AML patients. 23 Furthermore, the data shown here suggest that although CsA is an effective P-gpthat when KCN is used as the modulating agent, the daunorubicin accumulation assay sums the activities of all energymodulating agent, it may fail to improve treatment response to anthracyclines in some patients due to the existence of drug dependent processes that reduce drug uptake, whether these
